Market News

CGI Group Inc. (GIB) EPS Estimated At $0.82; Aqr Capital Management Has Upped By $54.09 Million Its Alexion Pharmaceuticals (ALXN) Holding

CGI Group Inc. (NYSE:GIB) Logo

Analysts expect CGI Group Inc. (NYSE:GIB) to report $0.82 EPS on May, 2 before the open.They anticipate $0.14 EPS change or 20.59% from last quarter’s $0.68 EPS. GIB’s profit would be $224.24M giving it 17.62 P/E if the $0.82 EPS is correct. After having $0.78 EPS previously, CGI Group Inc.’s analysts see 5.13% EPS growth. The stock decreased 0.21% or $0.12 during the last trading session, reaching $57.8. About 133,506 shares traded. CGI Group Inc. (NYSE:GIB) has risen 21.44% since April 23, 2017 and is uptrending. It has outperformed by 9.89% the S&P500.

Aqr Capital Management Llc increased Alexion Pharmaceuticals Inc (ALXN) stake by 48.15% reported in 2017Q4 SEC filing. Aqr Capital Management Llc acquired 454,570 shares as Alexion Pharmaceuticals Inc (ALXN)’s stock declined 8.80%. The Aqr Capital Management Llc holds 1.40 million shares with $167.26 million value, up from 944,006 last quarter. Alexion Pharmaceuticals Inc now has $23.97B valuation. The stock decreased 3.54% or $3.96 during the last trading session, reaching $107.78. About 5.46M shares traded or 150.17% up from the average. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 8.84% since April 23, 2017 and is downtrending. It has underperformed by 20.39% the S&P500.

Investors sentiment decreased to 1.03 in 2017 Q4. Its down 0.14, from 1.17 in 2017Q3. It turned negative, as 65 investors sold ALXN shares while 171 reduced holdings. 64 funds opened positions while 178 raised stakes. 204.38 million shares or 1.21% less from 206.89 million shares in 2017Q3 were reported. Advisor Partners Lc owns 2,345 shares. 3 were reported by Ent. Hartford reported 45,867 shares stake. Channing Mgmt Ltd Liability Company holds 125,278 shares or 0.51% of its portfolio. Virginia Retirement Et Al accumulated 152,200 shares. Edge Wealth Mngmt Lc owns 0.21% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 6,059 shares. Connor Clark & Lunn Invest has 193,500 shares. Art Lc holds 75,800 shares or 0.4% of its portfolio. 4,200 were reported by Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta. Nine Masts Ltd has invested 0.29% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Banque Pictet Cie accumulated 81,220 shares. Comerica Inc reported 3,245 shares stake. Hudock Capital Gru Lc owns 182 shares or 0.01% of their US portfolio. Private Na stated it has 7,909 shares or 0.2% of all its holdings. Amp Cap Invsts Ltd has invested 0.06% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Since January 2, 2018, it had 0 buys, and 12 selling transactions for $4.62 million activity. $83,305 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by Wagner Heidi L. HANTSON LUDWIG also sold $310,521 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, January 2. Another trade for 6,079 shares valued at $707,048 was made by Clancy Paul J on Tuesday, February 6. 2,119 shares valued at $248,474 were sold by O’Neill Julie on Monday, February 5. Goff Brian sold $192,028 worth of stock. Moriarty John B also sold $389,099 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, February 6. Franchini Indrani Lall sold $169,696 worth of stock.

Aqr Capital Management Llc decreased United Contl Hldgs Inc (NYSE:UAL) stake by 527,419 shares to 4.62M valued at $311.24M in 2017Q4. It also reduced Interdigital Inc (NASDAQ:IDCC) stake by 94,085 shares and now owns 161,610 shares. Red Hat Inc (NYSE:RHT) was reduced too.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 25 have Buy rating, 0 Sell and 4 Hold. Therefore 86% are positive. Alexion Pharmaceuticals Inc. had 105 analyst reports since July 27, 2015 according to SRatingsIntel. Piper Jaffray maintained the stock with “Buy” rating in Thursday, February 8 report. JP Morgan upgraded the shares of ALXN in report on Tuesday, September 5 to “Overweight” rating. The rating was maintained by Leerink Swann with “Buy” on Wednesday, September 13. The firm has “Buy” rating by Suntrust Robinson given on Thursday, January 7. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Stifel Nicolaus on Friday, October 27. The rating was maintained by Morgan Stanley on Friday, February 9 with “Overweight”. The firm has “Neutral” rating by Citigroup given on Thursday, February 25. The company was maintained on Tuesday, September 12 by Robert W. Baird. The firm has “Outperform” rating by BMO Capital Markets given on Wednesday, September 13. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Perform” rating given on Thursday, December 15 by Oppenheimer.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *